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A B S T R A C T
Direct oral anticoagulants (DOACs), apixaban, dabigatran, edoxaban, and rivaroxaban, are widely used 
for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation as 
well as for prevention and treatment of venous thromboembolism. Although DOACs do not require 
routine laboratory monitoring of anticoagulant effect, there are special situations in which laboratory 
assessment may be warranted. Laboratory tests include quantitative assays, which measure plasma 
DOAC levels, and qualitative or semi-quantitative assays, which may be used to screen for the presence 
of clinically relevant DOAC levels. Indications for laboratory assessment include emergent indications 
(serious bleeding, urgent surgery, acute ischemic stroke with consideration of thrombolysis) and 
elective indications (extremes of bodyweight, renal hypo- or hyperfunction, liver disease, suspected 
drug-drug interactions, suspected gastrointestinal malabsorption). In general, quantitative assays that 
measure DOAC levels may be used for elective indications, whereas screening assays may be necessary 
for emergent indications if a quantitative assay with sufficiently rapid turnaround time is not available. 
Therapeutic ranges for DOACs have not been defined. In lieu of therapeutic ranges, data from phar-
macokinetic studies may be used to determine whether a patient’s plasma DOAC level falls within 
the expected range. If it does not, a change in therapy may be warranted. Depending on the clinical 
scenario, a change in therapy may involve adjustment of the DOAC dose, a change to a different DOAC, 
or a change to a different class of anticoagulant. 
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INTRODUCTION 
Direct oral anticoagulant (DOAC) use has now outpaced 
vitamin K antagonists (VKAs) for various indications 
including non-valvular atrial fibrillation and treatment 
and prevention of venous thromboembolism (VTE) [1, 2]. 
There are four DOACs approved by the US Food and Drug 
Administration (FDA) that are available in the US, Europe, 
and other jurisdictions including the direct thrombin in-
hibitor, dabigatran, and the direct oral factor Xa inhibitors, 
rivaroxaban, apixaban, and edoxaban. The properties of 
these agents are summarized in Table 1. 
DOACs have several advantages compared with 
VKAs. They are associated with lower risk of major bleed-
ing including intracranial hemorrhage [3–7]. They also 
have a shorter half-life, quicker onset of action, and fewer 
dietary and drug-drug interactions [8, 9]. An additional 
advantage of DOACs is that they do not require routine 
laboratory monitoring of anticoagulant effect because they 
have a broad therapeutic window and more predictable 
pharmacokinetics than VKAs. Nevertheless, there are spe-
cial situations in which DOAC laboratory assessment may 
be warranted. In this review, we discuss laboratory assays 
for DOAC assessment and their interpretation. We also 
describe circumstances in which such testing is warranted 
and how the results may be used to guide management. 
LABORATORY ASSAYS FOR DOAC 
ASSESSMENT
Laboratory assays for DOAC assessment can be divided 
into quantitative tests used to measure plasma drug levels 
and qualitative or semi-quantitative tests used to screen 
for the presence of clinically relevant drug levels (Table 2).
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Assays for measuring drug levels
Liquid chromatography with tandem mass spectrometry 
(LC-MS/MS) is the gold standard for measuring DOAC lev-
els. However, it is not widely available in clinical practice, 
particularly when rapid turnaround is required [10, 11]. To 
meet the need for more rapid provision of results, simpler 
assays with greater availability have been developed for 
the measurement of dabigatran and direct oral factor 
Xa inhibitors that demonstrate close correlation with LC- 
-MS/MS (Table 2).
Dabigatran
When the dilute thrombin time (dTT) is used in conjunction 
with a drug calibrator, there is a strong linear relationship 
between dabigatran levels across a wide range of concen-
trations with less accuracy at levels <50–100 ng/ml [10–12]. 
Ecarin is a metalloprotease from the venom of the saw-
scaled viper (Echis carinatus) that cleaves prothrombin to 
the intermediate product meizothrombin, which is inhibit-
ed by dabigatran [10–12]. Ecarin-based assays including the 
ecarin clotting time (ECT) and ecarin chromogenic assay 
(ECA) demonstrate a strong linear correlation across a wide 
range of dabigatran concentrations with reduced accuracy 
at levels <50 ng/ml and >500 ng/ml [10, 12].
Oral factor Xa inhibitors (rivaroxaban, apixaban, 
edoxaban) 
For measurement of rivaroxaban, apixaban, and edoxaban, 
chromogenic anti-Xa assays calibrated with the drug of 
interest show a linear correlation across a wide range of 
concentrations. However, the correlation is less precise at 
lower drug levels (rivaroxaban level <30 ng/ml, apixaban 
<15 ng/ml, edoxaban <10 ng/ml) and at levels >500 ng/ml 
[10–12].
Screening assays to determine whether clinically 
relevant drug levels are present 
In many centers, assays for DOAC quantitation may not 
be available, particularly on a 24/7 basis. When such 
assays are not available, qualitative or semi-quantitative 
assays, which are more readily accessible, may be used 
to screen for the presence of clinically relevant drug 
levels (Table 2).
Dabigatran 
The thrombin time (TT) is widely available and is ex-
quisitely sensitive to even minor, clinically insignificant 
concentrations of dabigatran. Therefore, a normal TT 
excludes the presence of clinically significant levels of 
dabigatran, whereas a prolonged TT may indicate the 
presence of clinically significant or trivial levels of drug 
[13]. DOASENSE™ is a urine dipstick that provides a rapid 
qualitative assessment of the presence of dabigatran and 
is only available in Europe [11, 14]. Like the TT, a negative 
dipstick generally excludes the presence of clinically sig-
nificant plasma drug levels but a positive result cannot 
distinguish between clinically relevant and trivial plasma 
levels of dabigatran.
Table 1. Properties of direct oral anticoagulants
Dabigatran Rivaroxaban Apixaban Edoxaban
References [46, 47] [48, 49] [50] [51]
Mechanism of action Thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor
Bioavailability, % 3 80–100 (when taken with food)  50 62
Time to peak, hour  1–2 2–4  3–4 1–2
Protein binding, %  35 92–95  87 55
Half-life (normal renal 
function), hour
12–14 5–9 12 10–14
Metabolizers Major substrate of P-gp Major substrate of CYP3A4.
Minor substrate of P-gp
Major substrate of CYP3A4.
Minor substrate of P-gp
Major substrate of P-gp
Renal elimination, % ~80 ~66 ~27 ~50
Abbreviations: CYP, cytochrome P450; P-gp, P-glycoprotein
Table 2. Laboratory assays for direct oral anticoagulants 
 Dabigatran Rivaroxaban, Apixaban, Edoxaban







Chromogenic anti-Xa assay calibrated with drug of interest
Screening assays for excluding the presence of 
clinically significant drug levelsa
TTb
DOASENSE™c
Chromogenic heparin anti-Xa assayd
DOASENSE™c
a”Clinically significant drug levels” refers to DOAC levels that may contribute to bleeding risk. The minimum DOAC level that may contribute to bleeding risk is unknown. The 
International Society on Thrombosis and Haemostasis suggests consideration of DOAC reversal in patients with serious bleeding and a DOAC level >50 ng/ml and in patients 
undergoing a surgical procedure with high bleeding risk and a DOAC level >30 ng/ml. bA normal TT excludes the presence of clinically significant dabigatran levels. A pro-
longed TT may suggest the presence of clinically significant or trivial levels of dabigatran. cA negative DOASENSE™ generally excludes the presence of clinically significant 
DOAC levels. A positive DOASENSE™ may suggest the presence of clinically significant or trivial DOAC levels. dA chromogenic heparin anti-Xa assay below the lower limit of 
quantitation generally excludes the presence of clinically significant levels of rivaroxaban, apixaban, or edoxaban.
Abbreviations: DOAC, direct oral anticoagulants; dTT, dilute thrombin time; ECA, ecarin chromogenic assay; ECT, ecarin clotting time; LC-MS/MS, liquid chromatography- 
-tandem mass spectrometry; TT, thrombin time
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Oral factor Xa inhibitors (rivaroxaban, apixaban, 
edoxaban)
Chromogenic anti-Xa assays calibrated with heparin show 
less linearity and are therefore not suitable for quantifica-
tion of oral factor Xa inhibitors. However, a heparin anti-Xa 
level below the lower limit of quantitation is generally suf-
ficient to exclude clinically relevant drug levels [10, 11]. As 
with dabigatran, DOASENSE™ can be used to screen for oral 
factor Xa inhibitors. A negative dipstick generally excludes 
the presence of clinically significant plasma drug levels 
whereas a positive result may indicate the presence of 
clinically relevant or trivial levels of oral factor Xa inhibitor.
Prothrombin time and activated partial 
thromboplastin time 
Dabigatran and the oral factor Xa inhibitors prolong the 
prothrombin time (PT) and activated partial thromboplas-
tin time (APTT) in a dose-dependent manner. In general, 
the APTT is more sensitive to dabigatran and the PT is 
more sensitive to oral factor Xa inhibitors. Among oral 
factor Xa inhibitors, the PT and APTT are more sensitive 
to rivaroxaban and edoxaban than they are to apixaban. 
However, neither the PT nor APTT shows sufficient linearity 
to be suitable for DOAC quantitation. Moreover, the PT 
and APTT may remain normal in the presence of clinically 
relevant DOAC levels, depending on the sensitivity of the 
reagent [13]. Therefore, the PT and APTT cannot be relied 
upon as screening tests to exclude the presence of clinically 
significant drug levels. 
HOW TO INTERPRET DOAC LEVELS
In order to interpret a DOAC level correctly, it is useful to 
know when the drug was last taken. When possible, a peak 
and trough level should be drawn because expected plas-
ma drug levels have been defined for these time points 
(Table 3) [12]. However, there are situations in which it 
may be necessary to check a randomly timed level (e.g. in 
a patient with emergent bleeding) or in which it may not 
be possible to determine the time of last ingestion (e.g. in 
an unconscious patient). 
Although several studies have demonstrated a rela-
tionship between DOAC levels and clinical outcomes [15], 
therapeutic ranges have not been defined for DOACs and 
a strategy of dose-adjustment to target certain drug levels 
has not been tested in clinical trials. In lieu of therapeutic 
ranges, it is useful to consider the expected steady-state 
peak and trough levels for a given DOAC at a given dose 
(Table 3), which are based on pharmacokinetic studies 
[10–12].
The minimal DOAC level that may contribute to 
bleeding is unknown. Guidance from the International 
Society on Thrombosis and Haemostasis (ISTH) suggests 
that reversal may be warranted in a bleeding patient with 
a level >50 ng/ml or in a preoperative patient with a level 
>30 ng/ml, but it is important to emphasize that these 
thresholds are based on expert opinion rather than clinical 
evidence [16]. 
INDICATIONS FOR LABORATORY 
ASSESSMENT OF DOACS 
Indications for laboratory assessment of DOACs may be 
divided into emergent and elective indications. Labo-
ratory assessment for emergent indications must yield 
results within minutes in order to inform management 
decisions. At many centers, assays that measure DOAC 
levels are not available with such a short turnaround time 
and the clinician must rely on screening assays (Table 2). 
Conversely, a longer turnaround time of hours to days is 
acceptable for elective indications, allowing for the use 
of assays that measure DOAC levels (Table 2), even if they 
need to be sent out to a reference laboratory. 
Emergent indications 
Serious bleeding 
Patients on DOACs may experience serious or life-threat-
ening bleeding. In such situations, the clinician must make 
a rapid determination about whether to use a reversal 
agent. DOAC laboratory assessment can be a useful tool 
in guiding this decision [17]. If the result of a quantitative 
assay can be obtained quickly, a drug level >50 ng/ml 
may be used to justify the administration of a reversal 
agent, consistent with ISTH guidance [16]. More often, 
a quantitative assay will not be available with sufficiently 
rapid turnaround and the clinician will need to rely on 
a screening assay. In a patient taking dabigatran, a normal 
TT or DOASENSE™ would be justification for withholding 
a reversal agent. Similarly, reversal would not be warranted 
Table 3. Expected steady-state peak and trough direct oral anticoagulants (DOAC) concentrations





Dabigatran 150 mg bid 64–443a 31–225a [52, 53, 54]
Rivaroxaban 2.5 mg bid 28–70b 6–37b [48]
Rivaroxaban 20 mg daily 184–343a 12–137a [53, 55]
Apixaban 5 mg bid 69–321a 34–230a [53, 56]
Edoxaban 60 mg daily 91–321a 31–230a [53, 57]
Adapted from Hindricks et al. [53].
aIn patients taking a DOAC for atrial fibrillation. bIn patients taking a DOAC for secondary prevention of acute coronary syndromes
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in a patient taking an oral factor Xa inhibitor with a negative 
DOASENSE™ or a heparin anti-Xa level below the lower limit 
of quantification (Table 2). 
Incomplete or impermanent reversal has been reported 
with the DOAC reversal agents, idarucizumab and andex-
anet alfa. Uncommonly, repeat dosing of a reversal agent 
may be considered. In such cases, a quantitative assay to 
measure drug levels may be useful for determining the 
need for re-dosing [18].
Measurement of a DOAC level in a bleeding patient may 
also be useful for excluding drug concentrations above the 
expected range (Table 3), which could be due to accidental 
or intentional overdose or to a condition resulting in DOAC 
bioaccumulation (e.g. low body weight, renal or hepatic 
dysfunction, certain drug-drug interactions). 
Urgent surgery 
The Perioperative Anticoagulation Use for Surgery Evalua-
tion (PAUSE) study showed that DOAC levels generally do 
not need to be measured before elective procedures. More-
over, some procedures can be performed safely without 
interruption of anticoagulation [19, 20]. Nevertheless, 
DOAC laboratory assessment may be helpful prior to cer-
tain unplanned, urgent surgeries [19], especially if there 
is consideration for delaying the surgery or administering 
a reversal agent [17]. 
If the result of a quantitative assay can be obtained 
quickly, a drug level >30 ng/ml may be used to justify 
postponement of a high bleeding risk procedure or 
administration of a reversal agent, consistent with ISTH 
guidance [16]. If a quantitative assay is not available with 
a sufficiently rapid turnaround, the clinician may need to 
rely on a screening assay. In a patient taking dabigatran, 
a normal TT or DOASENSE™ would justify withholding 
a reversal agent [17]. Similarly, reversal would not be war-
ranted in a patient taking an oral factor Xa inhibitor with 
a negative DOASENSE™ or a heparin anti-Xa level below 
the lower limit of quantification (Table 2). 
Acute ischemic stroke, consideration of 
thrombolysis 
The American Heart Association/American Stroke Asso-
ciation 2018 guideline recommends against intravenous 
thrombolysis (IVT) in patients on DOACs who have taken 
their last dose within the previous 48 hours and have 
laboratory evidence of residual anticoagulant effect [21]. 
However, a recent expert review highlights that using time 
since the last dose of anticoagulation as a surrogate for 
DOAC activity is not always reliable due to pharmacokinetic 
variability among patients [22]. The authors recommend 
proceeding with IVT if at least 48 hours have elapsed 
since the last DOAC dose and the creatinine clearance 
is >50 ml/min. If the patient does not meet one or both 
criteria, DOAC laboratory assessment is recommended. 
For patients on dabigatran, IVT is only recommended if 
the dabigatran level is <30 ng/ml or the TT is normal. For 
patients on an oral factor Xa inhibitor, IVT is recommended 
if the drug level is <30 ng/ml and may be considered if 
the drug level is 30–100 ng/ml [22]. Clinical outcome data 
validating these recommendations are needed.
Measurement of a DOAC level in a DOAC-treated 
patient with stroke or other thromboembolic events may 
also be useful for excluding drug concentrations below the 
expected range (Table 3), which could be due to a condi-
tion resulting in low DOAC levels (e.g. high body weight, 
renal hyperfunction, certain drug-drug interactions, 
gastrointestinal malabsorption) or to non-adherence. It 
should be noted, however, that a DOAC level only indicates 
whether the patient took the prescribed drug in the last 
12 to 24 hours. Owing to the short half-life of the DOACs 
(Table 1), the measurement of DOAC levels is not a useful 
tool for assessing longer-term adherence. 
Elective indications 
Extremes of body weight 
Patients with extremes of body weight (e.g. <50 kg or 
>120 kg) had very limited representation in the pivotal trials 
that led to the approval of the DOACs. There is a theoretical 
concern that high body weight could be associated with 
subtherapeutic drug levels whereas low body weight could 
be associated with DOAC bioaccumulation. Based on these 
concerns, the ISTH has suggested that DOACs be avoided 
in patients weighing >120 kg or with a body mass index 
>40 kg/m2. If DOACs are to be used in this population, the 
ISTH recommends measuring DOAC peak and trough levels 
to ensure that they fall within the expected range (Table 3) 
[23]. The ISTH has not offered guidance for patients with 
low body weight. 
In spite of these cautions, clinical outcome evidence in 
patients with extremes of body weight, particularly high 
body weight, has been largely reassuring. In a meta-analysis 
and systematic review of 11 randomized controlled trials of 
DOACs in non-valvular atrial fibrillation and VTE, patients 
with high body weight did not have a greater risk of throm-
bosis than those with non-high body weight. Interestingly, 
patients with low body weight had an increased thrombotic 
risk, but not an increased bleeding risk compared with 
non-low bodyweight individuals [24]. In a retrospective 
analysis of 18,147 patients with VTE treated with DOACs, 
6-month readmission for recurrent VTE was not increased in 
the 13% of patients weighing >120 kg [25]. Another 5-year 
retrospective study found no difference in VTE recurrence 
in 133 patients weighing ≥120 kg compared to 1063 pa-
tients weighing <120 kg (0.8% vs 1.1%; OR, 0.66; 95% CI, 
0.09–5.14; P = 0.69) [26]. Apixaban for Reduction in Stroke 
and Other Thromboembolic Events in Atrial Fibrillation 
(n = 18,201), a randomized trial comparing apixaban with 
warfarin for the prevention of stroke in patients with atrial 
fibrillation, included 1,985 (10.9%) patients weighing ≤60 kg 
group and 982 (5.4%) patients weighing >120 kg. Apixaban 
was found to be efficacious and safe in both groups [27].
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Although these studies suggest that DOAC laboratory 
assessment may not be necessary in most adults with low 
or high body weight, they included few patients weighing 
<50 kg or >150 kg. Thus, it may be reasonable to consider 
the measurement of steady-state trough and peak levels 
in such patients to confirm they are within the expected 
range (Table 3). If levels are outside the expected range, 
transition to a VKA should be considered.
Renal hypo- or hyperfunction 
All 4 DOACs are partially cleared by the kidneys, with dab-
igatran being the most reliant (80%) on renal elimination 
(Table 1) [28]. DOAC levels are therefore inversely related 
to renal function. For example, in the pivotal trial of dab-
igatran for atrial fibrillation, subjects with a creatinine clear-
ance of 30–50 ml/min had a 2.29-fold greater dabigatran 
trough concentration than those with creatinine clearance 
≥80 ml/min [15]. Conversely, edoxaban was shown to be 
less efficacious in patients with atrial fibrillation and very 
robust renal function (i.e. creatinine clearance >95 ml/min), 
presumably due to lower plasma drug concentrations [28].
Dosing recommendations in the US FDA labels reflect 
the importance of renal function on DOAC levels and 
clinical outcomes [29–32]. Among patients with atrial 
fibrillation, edoxaban is contraindicated in patients with 
a creatinine clearance >95 ml/min. Dose-reduction is 
advised for edoxaban and rivaroxaban if the creatinine 
clearance is 15–50 ml/min, for dabigatran if the creatinine 
clearance is 15–30 ml/min, and for apixaban if the patient 
has at least two of three features (creatinine ≥1.5 ml/min, 
age ≥80, or weight ≤60 kg) that could contribute to reduced 
creatinine clearance [33]. 
While these dosing recommendations apply to patients 
with chronic kidney disease stages I through IV, there is 
greater controversy about anticoagulant selection and 
dosing in patients with stage V chronic kidney disease 
(creatinine clearance <15 ml/min or on dialysis) as well 
as in patients with rapidly changing renal function. In 
such patients, measurement of DOAC peak and trough 
levels may be useful in guiding management. For exam-
ple, identification of levels above the on-therapy range 
(Table  3) may justify changing to a different DOAC that 
is less reliant on renal clearance, to an entirely different 
class of anticoagulant such as a VKA, or discontinuation 
of anticoagulation altogether depending on the clinical 
context and indication. 
Liver disease
All 4 DOACs are variably metabolized by the liver with 
apixaban being the most reliant (75%) and dabigatran the 
least reliant (20%) on hepatic metabolism [34] Moreover, 
decreased albumin synthesis in patients with liver disease 
may affect levels of the free drug depending on the degree 
to which each agent is protein-bound (Table 1). 
Evidence on the use of DOACs in patients with mod-
erate or severe liver disease is limited. Such patients were 
excluded from the pivotal clinical trials. Small retrospective 
studies have been reported [35–37].
The US FDA recommends using the Child-Pugh score 
to guide dosing. Dose adjustment is not needed for any 
of the DOACs in patients with Child-Pugh class A (mild 
hepatic impairment). Caution or avoidance is advised for 
apixaban, edoxaban, and rivaroxaban in patients with 
moderate (Class B) or severe (Class C) liver disease [29–32, 
34]. Prescribing instructions differ in other jurisdictions 
including Europe and Canada. 
If a DOAC is to be used in a patient with moderate or 
severe liver disease, steady-state peak and trough levels 
may be useful for confirming that drug concentrations are 
within the expected range (Table 3). If a level is above the 
on-therapy range, it may be advisable to change to a differ-
ent DOAC that is less reliant on the liver for its metabolism 
or to change to a different class of anticoagulant (e.g. VKA, 
low molecular weight heparin).
Suspected drug-drug interactions
An important advantage of DOACs over VKAs is that DOACs 
have fewer drug-drug interactions. Nevertheless, DOACs 
are substrates of cytochrome p450 (particularly CYP3A4) 
as well as p-glycoprotein (P-gp) and drugs that inhibit or 
induce these systems may affect plasma DOAC concen-
trations [33, 38, 39]. CYP3A4 is important for metabolizing 
apixaban (20%–25%) and rivaroxaban (50%), but not 
dabigatran or edoxaban. Dabigatran and edoxaban are 
major substrates and apixaban and rivaroxaban are minor 
substrates of P-gp [39] (Table 1). 
Drug interactions can affect DOAC levels and, in turn, 
may influence clinical outcomes. A study of the Taiwanese 
national insurance database showed that concurrent use 
of dabigatran, rivaroxaban, or apixaban with amiodarone, 
fluconazole, rifampin, or phenytoin was associated with 
increased major bleeding [39, 40]. The FDA labels for DOACs 
acknowledge the risk posed by drug-drug interactions by 
recommending avoidance or dose-reduction with concom-
itant use of certain medications [29–32].
In addition to avoidance or dose-reduction, meas-
urement of drug levels may serve as a useful strategy for 
guiding management. Steady-state peak and trough levels 
in the expected range (Table 3) may provide reassurance 
that it is safe to continue a given drug combination. 
Conversely, a drug level outside of the expected range 
may suggest the need to adjust the dose of the DOAC, 
change to another DOAC that is less likely to have a potent 
interaction with the concomitant medication, change to 
a different class of anticoagulant (e.g. VKA), or stop the 
concomitant medication. 
Suspected gastrointestinal malabsorption 
A number of conditions could potentially be associated 
with malabsorption of DOACs including bariatric surgery, 
short-gut syndrome, inflammatory bowel disease, and 
other disorders of the gastrointestinal tract. 
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In a study of 9 patients who had undergone roux-en-y 
gastric bypass, the median peak dabigatran concentra-
tion was only 34.6 ng/ml, well below the expected range 
(Table 3) [41]. Another study compared peak DOAC levels 
in 18 bariatric surgery patients and 18 controls. Five (28%) 
patients in the bariatric group and 0 in the control group 
had peak levels below the expected range. All 5 patients 
with low levels were taking rivaroxaban. Other pharmacoki-
netic studies suggest reduced rivaroxaban absorption after 
sleeve gastrectomy or gastric banding [42].
The aforementioned pharmacokinetic evidence not-
withstanding, it remains uncertain whether reduced DOAC 
levels in bariatric surgery patients translate to inferior 
outcomes. A recent observational study of patients on oral 
anticoagulation for atrial fibrillation compared outcomes 
in 1,673 bariatric surgery patients with 155,619 non-bar-
iatric patients. The incidence of ischemic stroke/systemic 
embolism (0.83 vs 1.32 per 100 person years; HR, 0.62, 95% 
CI, 0.31–1.22; P = 0.17) and major bleeding (5.30 vs 4.87 per 
100 person years; HR, 1.05, 95% CI, 0.80–1.37; P = 0.73) was 
similar between the 2 groups [43].
There is scant information regarding DOAC absorption 
in other conditions. One small study demonstrated poten-
tially reduced dabigatran and rivaroxaban levels in patients 
with short-gut syndrome [44]. We are not aware of evidence 
on DOAC levels in other malabsorptive disorders including 
inflammatory bowel disease, celiac disease, or small bowel 
bacterial overgrowth.
If a patient with suspected gastrointestinal malab-
sorption is treated with a DOAC, it may be reasonable to 
measure steady-state peak and trough levels. If the levels 
are below the expected range (Table 3), suggestive of DOAC 
malabsorption, a change to a different anticoagulant such 
as a VKA may be warranted [45].
CONCLUSION
Although DOACs do not require routine laboratory moni-
toring of anticoagulant level, there are special circumstanc-
es in which laboratory assessment may be helpful in guid-
ing management. Indications for laboratory assessment of 
DOACs may be divided into emergent (serious bleeding, 
urgent surgery, acute ischemic stroke) and elective (ex-
tremes of bodyweight, renal hypo- or hyperfunction, 
liver disease, suspected drug-drug interaction, suspected 
gastrointestinal malabsorption). 
Our approach to patients with an emergent indication 
for laboratory assessment is summarized in Figure 1. If avail-
able with sufficiently rapid turnaround time, a randomly 
timed quantitative assay that measures plasma DOAC levels 
should be ordered. If a quantitative assay is not available, 
Serious bleeding, consideration 
for anticoagulant reversal
Urgent surgery, with high bleeding risk, 
consideration for anticoagulant reversal
Acute ischemic stroke, 
consideration for IVT
Laboratory assessmenta
• Quantitative assay for DOAC measurement 
(if available with rapid turnaround)
• Screening assay (if quantitative assay not available)
Interpretation
• Quantitative assay ≤50 ng/ml or 
negative screening assay Æ 
Reversal generally not indicated
• Quantitative assay >50 ng/ml or 
positive screening assay Æ 
Consider reversal
Interpretation
• Quantitative assay ≤30 ng/ml or 
negative screening assay Æ Proceed 
with surgery. Reversal generally not 
indicated
•  Quantitative assay >30 ng/ml or 
positive screening assay Æ Consider 
reversal or postponement of surgery
Interpretation
• Quantitative assay ≤30 ng/ml or 
negative screening assay 
Æ Proceed with IVT
• Quatitative assay >30 ng/ml or 
positive screening assay 
Æ Consider avoiding IVT
Figure 1. Approach to the patient with an emergent indication for direct oral anticoagulants (DOAC) laboratory assessment. Emergent 
indications for DOAC laboratory assessment include serious bleeding or urgent surgery with consideration for anticoagulant reversal or 
acute ischemic stroke with consideration for IVT. In a patient with an emergent indication for DOAC laboratory assessment, a randomly timed 
DOAC level should be measured using a quantitative assay. If a quantitative assay with sufficiently rapid turnaround time is not available, 
a screening assay should be used. In patients with serious bleeding and a DOAC level ≤50 ng/ml or a negative screening assay, anticoagulant 
reversal is generally not warranted. However, if the DOAC level is >50 ng/ml or a screening assay is positive, reversal should be considered 
depending on the type and severity of the bleed [16]. In patients who require urgent surgery with high bleeding risk, reversal is generally not 
warranted if the DOAC level is ≤30 ng/ml or a screening assay is negative. However, if the DOAC level is >30 ng/ml or a screening assay is po-
sitive, reversal or postponement of surgery should be considered depending on the nature and urgency of the surgery [16]. In patients with 
acute ischemic stroke and a DOAC level ≤30 ng/ml or a negative screening assay, IVT is likely to be safe. The maximum DOAC level at which 
IVT is safe is unknown. We suggest avoiding IVT if the DOAC level is >30 ng/ml or a screening assay is positive [21, 22]. aSee Table 2 for a list of 
assays that may be used for laboratory assessment of DOACs.
Abbreviations: IVT, intravenous thrombolysis
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a screening assay should be requested (Table 2). Threshold 
DOAC levels above which anticoagulant reversal or avoid-
ance of IVT is warranted have been proposed [16, 21, 22] 
and are listed in Figure 1. These thresholds are based largely 
on expert opinion. Clinical outcomes research is needed 
to refine and validate these thresholds. Development 
of simple, rapid, point-of-care quantitative assays is also 
needed so that measurement of plasma DOAC levels for 
emergent indications can be made accessible to a greater 
number of patients.
Our approach to patients with an elective indication for 
laboratory assessment is depicted in Figure 2. Steady-state 
peak and trough plasma DOAC levels should be measured 
using a quantitative assay (Table 2). Levels that fall within 
the expected range (Table 3) support the continuation 
of current management. Levels that fall outside the ex-
pected range should prompt consideration of a change 
in management, which may include adjustment of the 
DOAC dose, changing to a different DOAC, or changing to 
a different class of anticoagulant, depending on the clinical 
scenario. Further research is needed to better understand 
the relationship between plasma DOAC levels and clini-
cal outcomes.
While the development of improved assays and addi-
tional evidence linking DOAC levels and clinical outcomes is 
eagerly awaited, clinicians should be aware that laboratory 
assessment of DOACs using currently available methods 
may be used to guide the management of their patients 
in special situations. 
Article information
Conflict of interest: AC has served as a consultant for Synergy, has 
received authorship royalties from UpToDate, and his institution has 
received research support on his behalf from Alexion, Bayer, Novartis, 
Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. IJA has no conflicts 
to declare.
Open access: This article is available in open access under Creative 
Common Attribution-Non-Commercial-No Derivatives 4.0 Interna-
tional (CC BY-NC-ND 4.0) license, allowing to download articles and 
share them with others as long as they credit the authors and the 
publisher, but without permission to change them in any way or use 
them commercially. For commercial use, please contact the journal 
office at kardiologiapolska@ptkardio.pl.
How to cite: Akpan IJ, Cuker A. Laboratory assessment of the direct 
oral anticoagulants: who can benefit? Kardiol Pol. 2021; 79(6): 622–630, 
doi: 10.33963/KP.a2021.0021.
REFERENCES
1. Zhu J, Alexander GC, Nazarian SN, et al. Trends and variation in oral 
anticoagulant choice in patients with atrial fibrillation, 2010–2017. Phar-
macotherapy. 2018; 38(9): 907–920, doi: 10.1002/phar.2158, indexed in 
Pubmed: 29920705.
2. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial 
fibrillation: CHEST guideline and expert panel report. Chest. 2018; 
154(5): 1121–1201, doi: 10.1016/j.chest.2018.07.040, indexed in Pubmed: 
30144419.
3. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants com-
pared with vitamin K antagonists for acute venous thromboembolism: 
evidence from phase 3 trials. Blood. 2014; 124(12): 1968–1975, doi: 
10.1182/blood-2014-04-571232, indexed in Pubmed: 24963045.
4. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for 
prevention of stroke in atrial fibrillation: systematic review, network 
meta-analysis, and cost effectiveness analysis. BMJ. 2017; 359: j5058, doi: 
10.1136/bmj.j5058, indexed in Pubmed: 29183961.
5. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivarox-
aban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 
365(10): 883–891, doi: 10.1056/NEJMoa1009638, indexed in Pubmed: 
21830957.
6. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management 
associated with major bleeding in patients with atrial fibrillation treated 
with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 
2015; 36(20): 1264–1272, doi: 10.1093/eurheartj/ehu463.
7. Giugliano RP, Ruff CT, Wiviott SD, et al. Mortality in patients with atrial 
fibrillation randomized to edoxaban or warfarin: insights from the EN-
GAGE AF-TIMI 48 trial. Am J Med. 2016; 129(8): 850–857.e2, doi: 10.1016/j.
amjmed.2016.02.028, indexed in Pubmed: 26994510.
8. van Gorp RH, Schurgers LJ. New insights into the pros and cons of the 
clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagu-
lants (doacs). Nutrients. 2015; 7(11): 9538–9557, doi: 10.3390/nu7115479, 
indexed in Pubmed: 26593943.
9. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc 
Hematol Educ Program. 2013; 2013(1): 464–470, doi: 10.1182/asheduca-
tion-2013.1.464.
10. Cuker A. Laboratory measurement of the non-vitamin K antagonist 
oral anticoagulants: selecting the optimal assay based on drug, assay 
availability, and clinical indication. J Thromb Thrombolysis. 2016; 41(2): 
241–247, doi: 10.1007/s11239-015-1282-7, indexed in Pubmed: 26386967.
11. Gosselin RC, Adcock DM, Bates SM, et al. International Council for Stand-
ardization in Haematology (ICSH) recommendations for laboratory meas-
urement of direct oral anticoagulants. Thromb Haemost. 2018; 118(3): 
437–450, doi: 10.1055/s-0038-1627480, indexed in Pubmed: 29433148.
12. Samuelson BT, Cuker A, Siegal DM, et al. Laboratory assessment of the 
anticoagulant activity of direct oral anticoagulants: a systematic review. 
Figure 2. Approach to the patient with an elective indication for direct oral anticoagulants (DOAC) laboratory assessment. In a patient with 
an elective indication for DOAC laboratory assessment, steady-state peak and trough levels should be measured using a quantitative assay. 
Levels within the expected range support continuation of present management. A level outside the expected range should prompt consi-
deration of a change in management. Depending on the clinical context, a change in management may include adjusting the DOAC dose, 
changing to a different DOAC, or changing to an anticoagulant of a different class (see text for further details). aSee Table 2 for a list of assays 
that may be used for measurement of DOAC levels. bSee Table 3 for expected ranges for DOACs taken at standard doses
Elective indication 
for DOAC assessment 
Extremes of body weight







of steady-state peak 











Imo J Akpan, Adam Cuker, Lab assessment of DOACs
w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
Chest. 2017; 151(1): 127–138, doi: 10.1016/j.chest.2016.08.1462, indexed 
in Pubmed: 27637548.
13. Tripodi A, Ageno W, Ciaccio M, et al. Position paper on laboratory testing 
for patients on direct oral anticoagulants. A consensus document from 
the SISET, FCSA, sibioc and sipmel. Blood Transfus. 2018; 16(5): 462–470, 
doi: 10.2450/2017.0124-17, indexed in Pubmed: 29106357.
14. Patel JP, Byrne RA, Patel RK, et al. Progress in the monitoring of direct 
oral anticoagulant therapy. Br J Haematol. 2019; 184(6): 912–924, doi: 
10.1111/bjh.15756, indexed in Pubmed: 30697708.
15. Reilly PA, Lehr T, Haertter S, et al. RE-LY Investigators. The effect of 
dabigatran plasma concentrations and patient characteristics on the 
frequency of ischemic stroke and major bleeding in atrial fibrillation 
patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoag-
ulation Therapy). J Am Coll Cardiol. 2014; 63(4): 321–328, doi: 10.1016/j.
jacc.2013.07.104, indexed in Pubmed: 24076487.
16. Levy JH, Ageno W, Chan NC, et al. Subcommittee on Control of Anticoag-
ulation. When and how to use antidotes for the reversal of direct oral anti-
coagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 
14(3): 623–627, doi: 10.1111/jth.13227, indexed in Pubmed: 26911798.
17. Crowther M, Cuker A. How can we reverse bleeding in patients 
on direct oral anticoagulants? Kardiol Pol. 2019; 77(1): 3–11, doi: 
10.5603/KP.a2018.0197, indexed in Pubmed: 30338501.
18. Simon A, Domanovits H, Ay C, et al. The recommended dose of idaruci-
zumab may not always be sufficient for sustained reversal of dabigatran. J 
Thromb Haemost. 2017; 15(7): 1317–1321, doi: 10.1111/jth.13706, indexed 
in Pubmed: 28426914.
19. Douketis J, Spyropoulos A, Duncan J, et al. Perioperative management 
of patients with atrial fibrillation receiving a direct oral anticoagulant. 
JAMA Intern Med. 2019; 179(11): 1469–1478, doi: 10.1001/jamaint-
ernmed.2019.2431, indexed in Pubmed: 31380891.
20. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: 
Guidance from the Anticoagulation Forum. Am J Hematol. 2019; 94(6): 
697–709, doi: 10.1002/ajh.25475, indexed in Pubmed: 30916798.
21. Powers W, Rabinstein A, Ackerson T, et al. 2018 guidelines for the 
early management of patients with acute ischemic stroke: a guide-
line for healthcare professionals from the American Heart Associa-
tion/American Stroke Association. Stroke. 2018; 49(3): e46–e99, doi: 
10.1161/str.0000000000000158.
22. Seiffge DJ, Meinel T, Purrucker JC, et al. Recanalisation therapies for acute 
ischaemic stroke in patients on direct oral anticoagulants. J Neurol Neu-
rosurg Psychiatry. 2021; 92(5): 534–541, doi: 10.1136/jnnp-2020-325456, 
indexed in Pubmed: 33542084.
23. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral 
anticoagulants in obese patients: guidance from the SSC of the ISTH. J 
Thromb Haemost. 2016; 14(6): 1308–1313, doi: 10.1111/jth.13323, indexed 
in Pubmed: 27299806.
24. Boonyawat K, Caron F, Li A, et al. Association of body weight with efficacy 
and safety outcomes in phase III randomized controlled trials of direct 
oral anticoagulants: a systematic review and meta-analysis. J Thromb 
Haemost. 2017; 15(7): 1322–1333, doi: 10.1111/jth.13701, indexed in 
Pubmed: 28407368.
25. Younis M, Elkaryoni A, Williams GW, et al. The use of direct oral anticoag-
ulants in the management of venous thromboembolism in patients with 
obesity. Cureus. 2020; 12(8): e10006, doi: 10.7759/cureus.10006, indexed 
in Pubmed: 32983703.
26. Aloi KG, Fierro JJ, Stein BJ, et al. Investigation of direct-acting oral anti-
coagulants and the incidence of venous thromboembolism in patients 
weighing ≥120 kg compared to patients weighing <120 kg. J Pharm 
Pract. 2021; 34(1): 64–69, doi: 10.1177/0897190019854578, indexed in 
Pubmed: 31238775.
27. Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban 
versus warfarin in patients with atrial fibrillation and extremes in body 
weight. Circulation. 2019; 139(20): 2292–2300, doi: 10.1161/CIRCULATIO-
NAHA.118.037955, indexed in Pubmed: 30773022.
28. Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. 
The 2018 European Heart Rhythm Association Practical Guide on the 
use of non-vitamin K antagonist oral anticoagulants in patients with 
atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393, doi: 10.1093/eu-
rheartj/ehy136, indexed in Pubmed: 29562325.
29. Food and Drug Administration. Pradaxa — prescribing information. https://
www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf 
(April 27, 2021).
30. Food and Drug Administration. Xarelto — prescribing information. ttp://
www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.
pdf (April 27, 2021).
31. Food and Drug Administration. Eliquis — prescribing information. https://
www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.
pdf (April 27, 2021).
32. Food and Drug Administration. Edoxaban — prescribing information. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.
pdf (April 27, 2021).
33. Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical 
guide to common clinical challenges. J Am Heart Assoc. 2020; 9(13): 
e017559, doi: 10.1161/JAHA.120.017559, indexed in Pubmed: 32538234.
34. Qamar A, Vaduganathan M, Greenberger NJ, et al. Oral anticoagulation 
in patients with liver disease. J Am Coll Cardiol. 2018; 71(19): 2162–2175, 
doi: 10.1016/j.jacc.2018.03.023, indexed in Pubmed: 29747837.
35. Hum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anti-
coagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017; 
98(4): 393–397, doi: 10.1111/ejh.12844, indexed in Pubmed: 28009449.
36. Huang ZC, Li CQ, Liu XY, et al. Efficacy and safety of direct oral anticoag-
ulants in patients with atrial fibrillation and liver disease: a meta-analysis 
and systematic review. Cardiovasc Drugs Ther. 2020 [Epub ahead of 
print], doi: 10.1007/s10557-020-07065-y, indexed in Pubmed: 32880804.
37. Hoolwerf EW, Kraaijpoel N, Büller HR, et al. Direct oral anticoagulants 
in patients with liver cirrhosis: a systematic review. Thromb Res. 2018; 
170: 102–108, doi: 10.1016/j.thromres.2018.08.011, indexed in Pubmed: 
30153564.
38. Bellesini M, Bianchin M, Corradi C, et al. Drug-drug interactions between 
direct oral anticoagulants and hepatitis C direct-acting antiviral agents: 
looking for evidence through a systematic review. Clin Drug Investig. 
2020; 40(11): 1001–1008, doi: 10.1007/s40261-020-00962-y, indexed in 
Pubmed: 32809123.
39. Wiggins BS, Dixon DL, Neyens RR, et al. Select drug-drug interactions 
with direct oral anticoagulants: JACC review topic of the week. J Am Coll 
Cardiol. 2020; 75(11): 1341–1350, doi: 10.1016/j.jacc.2019.12.068, indexed 
in Pubmed: 32192661.
40. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin 
K oral anticoagulants with and without concurrent medications and risk 
of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017; 318(13): 
1250–1259, doi: 10.1001/jama.2017.13883, indexed in Pubmed: 28973247.
41. Grainger B, Holloway R, Merriman E, et al. Evidence of impaired dabigatran 
absorption following laparoscopic Roux-en-Y gastric bypass surgery: the 
Auckland regional experience (2011–2018). Br J Haematol. 2020; 191(2): 
e67–e69, doi: 10.1111/bjh.17004, indexed in Pubmed: 32720718.
42. Rottenstreich A, Barkai A, Arad A, et al. The effect of bariatric surgery on 
direct-acting oral anticoagulant drug levels. Thromb Res. 2018; 163: 190–
195, doi: 10.1016/j.thromres.2017.11.006, indexed in Pubmed: 29157916.
43. Hendricks AK, Zieminski JJ, Yao X, et al. Safety and efficacy of oral anti-
coagulants for atrial fibrillation in patients after bariatric surgery. Am J 
Cardiol. 2020; 136: 76–80, doi: 10.1016/j.amjcard.2020.09.020, indexed 
in Pubmed: 32941819.
44. Cheung YW, Barco S, Mathôt RAA, et al. Pharmacokinetics of dabigatran 
etexilate and rivaroxaban in patients with short bowel syndrome requiring 
parenteral nutrition: The PDER PAN study. Thromb Res. 2017; 160: 76–82, 
doi: 10.1016/j.thromres.2017.10.025, indexed in Pubmed: 29127863.
45. Martin KA, Lee CR, Farrell TM, et al. Oral anticoagulant use after bariatric 
surgery: a literature review and clinical guidance. Am J Med. 2017; 130(5): 
517–524, doi: 10.1016/j.amjmed.2016.12.033, indexed in Pubmed: 
28159600.
46. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of phar-
macology and management of bleeding complications of this novel oral 
anticoagulant. J Med Toxicol. 2011; 7(4): 281–287, doi: 10.1007/s13181-
011-0178-y, indexed in Pubmed: 21887485.
47. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin 
inhibitor. Circulation. 2011; 123(13): 1436–1450, doi: 10.1161/CIRCULA-
TIONAHA.110.004424, indexed in Pubmed: 21464059.
630
K A R D I O L O G I A  P O L S K A ,  2 0 2 1 ;  7 9  ( 6 )
w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
48. Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and 
pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014; 53(1): 
1–16, doi: 10.1007/s40262-013-0100-7, indexed in Pubmed: 23999929.
49. Stampfuss J, Kubitza D, Becka M, et al. The effect of food on the absorption 
and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013; 
51(7): 549–561, doi: 10.5414/CP201812, indexed in Pubmed: 23458226.
50. Byon W, Garonzik S, Boyd RA, et al. Apixaban: a clinical pharmacokinetic 
and pharmacodynamic review. Clin Pharmacokinet. 2019; 58(10): 1265–
1279, doi: 10.1007/s40262-019-00775-z, indexed in Pubmed: 31089975.
51. Kubli KA, Snead JA, Cheng-Lai A. Edoxaban: a novel factor xa in-
hibitor for the management of non-valvular atrial fibrillation and 
venous thromboembolism. Cardiol Rev. 2016; 24(4): 205–210, doi: 
10.1097/CRD.0000000000000104, indexed in Pubmed: 26991962.
52. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without 
concomitant aspirin compared with warfarin alone in patients with 
nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100(9): 
1419–1426, doi: 10.1016/j.amjcard.2007.06.034, indexed in Pubmed: 
17950801.
53. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 
2020 ESC Guidelines for the diagnosis and management of atrial fibril-
lation developed in collaboration with the European Association for 
Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498, doi: 
10.1093/eurheartj/ehaa612, indexed in Pubmed: 32860505.
54. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate — a novel, 
reversible, oral direct thrombin inhibitor: interpretation of coagulation as-
says and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 
1116–1127, doi: 10.1160/TH09-11-0758, indexed in Pubmed: 20352166.
55. Burghaus R, Coboeken K, Gaub T, et al. Evaluation of the efficacy and 
safety of rivaroxaban using a computer model for blood coagulation. 
PLoS One. 2011; 6(4): e17626, doi: 10.1371/journal.pone.0017626, indexed 
in Pubmed: 21526168.
56. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharma-
codynamics of multiple oral doses of apixaban, a factor Xa inhibitor, 
in healthy subjects. Br J Clin Pharmacol. 2013; 76(5): 776–786, doi: 
10.1111/bcp.12106, indexed in Pubmed: 23451769.
57. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant 
activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015; 
39(3): 288–294, doi: 10.1007/s11239-015-1185-7, indexed in Pubmed: 
25669624.
